Stay updated on IBI310 Combo vs Sorafenib in HCC Clinical Trial
Sign up to get notified when there's something new on the IBI310 Combo vs Sorafenib in HCC Clinical Trial page.

Latest updates to the IBI310 Combo vs Sorafenib in HCC Clinical Trial page
- Check7 days agoChange DetectedRecruitment status updated to no longer looking for participants. The history now includes a new revision entry (v3.6.0) to document this update.SummaryDifference0.4%

- Check14 days agoChange DetectedThe history now includes a new entry for Revision: v3.5.5, and the previous Revision: v3.5.4 entry has been removed, reflecting a small platform update to the record history display.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe page's revision tag moved from v3.5.3 to v3.5.4, indicating a new version of the record history. This reflects an update to the page's metadata rather than changes to the underlying study data.SummaryDifference0.1%

- Check50 days agoChange DetectedThe Record History shows the latest revision updated to v3.5.3, replacing the previous v3.5.2. This indicates a new version of the study record has been published.SummaryDifference0.1%

- Check64 days agoChange DetectedRevision: v3.5.2 was added to the record history, and revision v3.5.0 was removed.SummaryDifference0.1%

- Check86 days agoChange DetectedRevision v3.5.0 adds Study Status, Contacts/Locations, and Study Design and marks the study as Completed; the prior update removed the Recruiting status and sponsor Innovent Biologics (Suzhou) Co. Ltd.SummaryDifference2%

Stay in the know with updates to IBI310 Combo vs Sorafenib in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IBI310 Combo vs Sorafenib in HCC Clinical Trial page.